Suchergebnisse - "Balar, Arjun V"

PubPharm (12)

1

Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer : A Multicenter, Single-Arm, Phase II Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Funt, S. | Lattanzi, M. | Whiting, K. | +36

CommentIn: J Clin Oncol. 2022 Aug 10;40(23):2656. - PMID 35609220

2

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201) : a multicentre, single-arm, phase 2 trial

enthalten in: The Lancet. Oncology | 2021

von Yu, E. | Petrylak, D. | O'Donnell, P. | +17

CommentIn: Lancet Oncol. 2021 Jun;22(6):748-749. - PMID 33991513

3

PIVOT-10 : Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer

enthalten in: Future oncology (London, England) | 2021

von Huddart, R. | Siefker-Radtke, A. | Balar, A. | +15

4

Long-Term Outcomes in KEYNOTE-052 : Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020

von Vuky, J. | Balar, A. | Castellano, D. | +13

5

Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052) : Outcomes in Older Patients by Age and Performance Status

enthalten in: European urology oncology | 2020

von Grivas, P. | Plimack, E. | Balar, A. | +11

6

Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer

enthalten in: The oncologist | 2019

von Osterman, C. | Babu, D. | Geynisman, D. | +13

CommentIn: Oncologist. 2019 May;24(5):580-583. - PMID 30926675

7

Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2018

von Iyer, G. | Balar, A. | Milowsky, M. | +28

CommentIn: Eur Urol. 2019 Dec;76(6):870-871. - PMID 31351667

8

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052) : a multicentre, single-arm, phase 2 study

enthalten in: The Lancet. Oncology | 2017

von Balar, A. | Castellano, D. | O'Donnell, P. | +12

CommentIn: Lancet Oncol. 2017 Nov;18(11):1428-1430. - PMID 28967486

9

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma : a single-arm, multicentre, phase 2 trial

enthalten in: Lancet (London, England) | 2017

von Balar, A. | Galsky, M. | Rosenberg, J. | +33

CommentIn: Lancet. 2017 Jan 7;389(10064):6-7. - PMID 27939401

10

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy : a single-arm, multicentre, phase 2 trial

enthalten in: Lancet (London, England) | 2016

von Rosenberg, J. | Hoffman-Censits, J. | Powles, T. | +28

CommentIn: Lancet. 2016 May 7;387(10031):1881-2. - PMID 26952549